ASH 2022 | Efficacy & tolerability of anti-thrombotic therapy in patients with HHT
Hanny Al-Samkari, MD, Massachusetts General Hospital, Boston, MA, shares insights into a study that assessed the efficacy of anti-thrombotic therapy against hereditary hemorrhagic telangiectasia (HHT) – using a large cohort of patients receiving anti-thrombotic therapy with detailed patient-level data. This study demonstrated that patients with HHT respond poorly to antithrombotic therapy, and highlights a strong need for alternative anticoagulation therapies. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Argenx: Consultancy; Novartis: Consultancy; Moderna: Consultancy; Dova: Consultancy, Research Funding; Forma: Consultancy; Rigel: Consultancy; Amgen: Research Funding; Sobi: Consultancy, Research Funding; Agios: Consultancy, Research Funding.
